Biopolymers and colonic delivery

Modified-Release Drug Delivery Technology, Second Edition

Volumn 1, Issue , 2008, Pages 295-309

  Wilson, Clive G ^a   Mukherji, Gour ^b   Shah, Hardik K ^c  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b Jubilant Organosys Ltd   (India)

^c Biovail Technologies Ltd   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84894032883     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (44)

1. Rubinstein A, Gliko-Kabir I. Synthesis and swelling dependent enzymatic degradation of borax modified guar gum for colonic delivery purposes. STP Pharma Sci 1995; 5: 41-6.
2. Tomlin A, Read NW, Edwards CA, Duerden BI. The degradation of guar gum by a faecal incubation system. Br J Nutr 1986; 55: 481-6.
3. Wong D, Larrabee S, Clifford K, Tremblay J, Friend DR. USP dissolution apparatus III (reciprocating cylinder) for screening of guar-based colonic delivery formulations. J Control Release 1997; 47: 173-9.
4. Krishnaiah YSR, Satyanarayana S, Prasad YVR, Rao SN. Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy human volunteers. J Control Release 1998; 55: 245-52.
5. Tugcu-Demiroz F, Acarturk F, Takka S, Konus-Boyunaga O. In vitro and in vivo evaluation of mesalazine-guar gum matrix tablets for colonic drug delivery. J Drug Target 2004; 12(2): 105-12.
6. Sinha VR, Kumria R. Colonic drug delivery of 5-fluorouracil: an in vitro evaluation. Int J Pharm 2003; 249: 23-31.
7. Sinha VR, Mittal BR, Kumria K. In vivo evaluation of time and site of disintegration of polysaccharide tablet prepared for colon-specific drug delivery. Int J Pharm 2005; 289: 79-85.
8. Rubinstein A, Nakar D, Sintov A. Colonic drug delivery: enhanced release of indomethacin from cross-linked chondroitin matrix in rat cecal content. Pharm Res 1992; 9(2): 276-8.
9. Schols HA, Voragen AGJ. Complex pectins: structure elucidation using enzymes. In: Visser J Voragen AGJ, eds. Pectins and Pectinases. Amsterdam, The Netherlands: Elsevier Science, 1996: 3-19.
10. Dongowski G, Lorenz A, Anger H. Degradation of pectins with different degrees of esterification by Bacteroides thetaiotamicron isolated from human gut flora. Appl Environ Microbiol 2000; 66(4): 1321-7.
11. Sande SA. Pectin-based oral drug delivery to the colon. Expert Opin Drug Deliv 2005; 2(3): 441-50.
12. Mura P, Maestrelli F, Cirri M, Luisa Gonzalez Rodriguez M, Rabasco Alvarez AM. Development of enteric-coated pectin-based matrix tablets for colonic delivery of theophylline. J Drug Target 2003; 11(6): 365-71.
13. Ashford M, Fell J, Attwood D, Sharma H, Woodhead P. Studies on pectin formulations for colonic drug delivery. J Control Release 1994; 30: 225-32.
14. Sriamornsak P, Prakongpan S, Puttipipatkhachorn S, Kennedy RA. Development of sustained release theophylline pellets coated with calcium pectinate. J Control Release 1997; 47: 221-32.
15. Muhiddinov Z, Khalikov D, Speaker T, Fassihi R. Development and characterization of different low methoxy pectin microcapsules by an emulsion- interface reaction technique. J Microencapsulation 2004; 21(7): 729-41.
16. Dupuis G, Chambin O, Genelot C, Champion D, Pourcelot Y. Colonic drug delivery: influence of cross linking agent on pectin beadsproperties and role of capsule shell type. Drug Dev Ind Pharm 17 2006; 32(7): 847-55.
17. Wakerly Z, Fell JT, Attwood D, Parkins D. Pectin/ethylcellulose film coating formulations for colonic drug delivery. Pharm Res 1996; 13(8): 1210-12.
18. Munjeri O, Collett JH, Fell JT. Hydrogel beads based on amidated pectins for colon-specific drug delivery: the role of chitosan in modifying drug release. J Control Release 1997; 46: 273-8.
19. Adkin DA, Kenyon CJ, Lerner EI, et al. The use of scintigraphy to provide ‘Proof of Concept’ for novel polysaccharide preparations designed for colonic drug delivery. Pharm Res 1997; 14(1): 103-7.
20. Milojevic S, Newton JM, Cummings JH, et al. Amylose as a coating for drug delivery to the colon: preparation and in vitro evaluation using 5-aminosalicylic acid pellets. J Control Release 1996; 38: 75-84.
21. Ring SG, Archer DB, Allwood MC, Newton JM. Delayed release formulations. US Patent 5294448, March 15, 1994.
22. Cartilier L, Moussa I, Chebli C, Buczkowski S. Substituted amylose as a matrix for sustained drug release. US Patent 5879707, March 9, 1999.
23. Wilson PJ, Basit AW. Exploiting gastrointestinal bacteria to target drug to the colon: An in vitro study using amylose coated tablets. Int J Pharm 2005; 300: 89-94.
24. Simonsen L, Hovgaard L, Mortensen PB, Brondsted H. Dextran hydrogels for colon-specific drug delivery 5. Degradation in human intestinal incubation models. Eur J Pharm Sci 1995; 3: 329-37.
25. Hovgaard L, Brondsted H. Dextran hydrogels for colon-specific drug delivery. J Control Release 1995; 36: 159-66.
26. Ahmad S, Tester RF, Corbett A, Karkalas J. Dextran and 5-aminosalicylic acid (5-ASA) conjugates: synthesis, characterisation and enzymic hydrolysis. Carbohydr Res 2006; 341: 2694-701.
27. Watts P. Colonic drug delivery composition. US Patent 6228396, May 8, 2001.
28. Watts P, Smith A. TARGIT technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract. Expert Opin Drug Deliv 2005; 2(1): 159-67.
29. Tominaga S, Takizawa T, Yamada M. Large intestinal delivery composite. US Patent 6248362, June 19, 2001.
30. Raghavan CV, Muthulingam C, Amaladoss J, Jenita JL. An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. Chem Pharm Bull 2002; 50: 892-5.
31. Tozaki H, Odoriba T, Okada N, et al. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J Control Release 2002; 82: 51-61.
32. Wilson CG, Mukherji G. Glucosamine-polyacrylate inter-polymer complex and applications thereof. Patent: WO 03/067952, 2003.
33. Wood WE, Beaverson NJ. Barrier material comprising a thermoplastic and a compatible cyclodextrin derivative. US Patent 6218013, April 17, 2001.
34. Uekama K, Minami K, Hirayama F. 6(A)-O-[(4-biphenylyl)acetyl]-alpha-, beta- and gamma-cyclodextrins and 6(A)-deoxy-6(A)-[[(4-biphenylyl)acetyl]- amino]-alpha-, beta- and gamma-cyclodextrins: potential prodrugs for colonspecific delivery. Med Chem 1997; 40: 2755-61.
35. Siefke V, Weckenmann HP, Bauer KH. β-Cyclodextrin matrix films for colonspecific drug delivery. Proc Int Symp Control Rel Bioact Mater 1993; 20: 182.
36. Zou M, Okamoto H, Cheng G, Hao X, Sun J, Cui F, Danjo K. Synthesis and properties of polysaccharide produrgs of 5-aminosalicylic acid as potential colon-specific delivery systems. Eur J Pharm Biopharm 2005; 59: 155-60.
37. Vervoort L, Kinget R. In vitro degradation by colonic bacteria of inulin HP incorporated in Eudragit RS films. Int J Pharm 1996; 129(1-2): 185-90.
38. Cavalcanti OA, Van den Mooter G, Caramico-Soares I, Kinget R. Polysaccharides as excipients for colon-specific coatings. Permeability and swelling properties of casted films. Drug Dev Ind Pharm 2002; 28(2): 157-64.
39. Vervoort L, Van den Mooter G, Augustins P, Bousson R, Toppet S, Kinget R. Inulin hydrogels as carriers for colonic drug targeting: I. Synthesis and characterization of methacrylated inulin and hydrogen formation. Pharm Res 1997; 14(2): 1730-37.
40. Vervoort L, Rombaut P, Van den Mooter G, Augustins P, Kinget R. Inulin hydrogels. II. In vitro degradation study. Int J Pharm 1998; 172(1-2): 137-45.
41. Van den Mooter G, Vervoort L, Kinget R. Characterisation of methacrylated inulin hydrogels designed for colon targeting: In vitro release of BSA. Pharm Res 2003; 20: 303-7.
42. Akhgari A, Farahmand F, Garekani HA, Sadeghi F, Vandamme TF. Permeability and swelling studies of free films containing inulin in combination with different polymethacrylates aimed for colonic drug delivery. Eur J Pharm Sci 2006; 28: 307-14.
43. Kakoulides EP, Smart JD, Tsibouklis J. Azocrosslinked poly(acrylic acid) for colonic delivery and adhesion specificity: in vitro degradation and preliminary ex vivo bioadhesion studies. J Control Release 1998; 54: 95-109.
44. Van der Mooter G. Colon drug delivery. Expert Opin Drug Deliv 2007; 3(1): 111-25.